NA-Semax
Nootropic PeptidePreclinicalAlso known as: N-Acetyl-Semax, N-acetyl-l-aspartyl-Semax, NAA-Semax, Semax NA, Acetyl Semax
NA-Semax is the N-acetyl-l-aspartyl variant of Semax — the original ACTH(4-7) Pro-Gly-Pro analog developed at the Russian Academy of Sciences in the 1990s. The aspartate addition at the N-terminus is reported to improve metabolic stability against aminopeptidase cleavage, extending the in vivo half-life from minutes (parent Semax) to plausibly tens of minutes after intranasal dosing. As of 2026, NA-Semax sits in the same research-peptide tier as standard Semax — it is not FDA-approved for any indication and is sold as a research chemical with limited peer-reviewed primary literature on the acetylated variant specifically.
Overview
At A Glance
Mechanism of action — pharmacological summary:…
Mechanism of Action
Mechanism of action — pharmacological summary:
- BDNF upregulation — like the parent Semax, NA-Semax is reported to increase brain-derived neurotrophic factor expression in cortex and hippocampus, the same neuroplasticity pathway implicated in long-term cognitive enhancement and depression resolution.
- Dopaminergic modulation — increases dopamine release in mesolimbic motivation circuits (VTA → NAc), with reported D2 receptor sensitization at chronic doses. The acute "drive boost" subjective effect users describe is consistent with this mechanism.
- Serotonergic and noradrenergic effects — small but reproducible increases in 5-HT and NE turnover in rodent cortical slices.
- Anti-inflammatory — reduced IL-6 and TNF-α in models of acute neuroinflammation.
- Aminopeptidase resistance — N-terminal acetylation slows enzymatic cleavage, extending in vivo half-life vs. unmodified Semax. Direct PK head-to-head studies remain unpublished.
Overview
NA-Semax is the N-acetyl-l-aspartyl variant of Semax — the original ACTH(4-7) Pro-Gly-Pro analog developed at the Russian Academy of Sciences in the 1990s. The aspartate addition at the N-terminus is reported to improve metabolic stability against aminopeptidase cleavage, extending the in vivo half-life from minutes (parent Semax) to plausibly tens of minutes after intranasal dosing.
As of 2026, NA-Semax sits in the same research-peptide tier as standard Semax — it is not FDA-approved for any indication and is sold as a research chemical with limited peer-reviewed primary literature on the acetylated variant specifically. Most published Semax pharmacology applies by analogy, with the caveat that the half-life difference may shift optimal dosing frequency.
Reported nonclinical pharmacology mirrors Semax: BDNF upregulation, dopaminergic modulation in mesolimbic circuits, and increased serotonin and dopamine turnover in the cortex and hippocampus. The N-acetyl modification is reported to improve blood-brain-barrier transport, though direct PK comparisons in published literature remain thin.
Chemical Information
IUPAC Name
Not yet available
CAS Number
Not yet available
Molecular Formula
C40H56N12O11
Molecular Mass
893.0 g/mol
Dosing & Protocols
Unlock Dosing Protocols
Create a free account to:
- View beginner, intermediate & advanced protocols
- See weight-based dosing calculations
- Access cycle length & frequency data
Join 2,800+ researchers
Research
Unlock Research Data
Create a free account to:
- Browse PubMed study summaries
- See clinical trial phases & results
- Access mechanism of action details
Join 2,800+ researchers
Interactions
Interaction and contraindication data is being compiled for NA-Semax. Check back soon.
General Safety Note
Always consult a qualified healthcare professional before combining research compounds. Interactions may exist that are not yet documented.
No listings found for NA-Semax.
Related Compounds
View AllAdalank
Nootropic PeptidePreclinicalAdalank is a hybrid research peptide combining structural elements of Adamax (the adamantane-modified Semax analog) and Selank (the anxiolytic Pro-Gly-Pro tuftsin analog).
Adamax
Nootropic PeptidePreclinical / Research compoundAdamax is a synthetic nonapeptide (Ac-MEHFPGPAG-NH2) classified as a designer analog of Semax.
NA-Semax Amidate
Nootropic PeptidePreclinicalNA-Semax Amidate is the C-terminally amidated NA-Semax — the carboxylic acid at the peptide's C-terminus is replaced with an amide group (-NH2), which is reported to further extend metabolic half-life by resisting carboxypeptidase cleavage in addition to the aminopeptidase resistance the N-acetyl group already provides. The practical effect is a peptide with dosing-frequency leverage: where standard Semax often requires 3-4 daily doses to maintain effect, NA-Semax Amidate is reported (in vendor monographs and community usage) to maintain subjective effects on a 1-2x daily schedule.
P-21
Nootropic PeptidePreclinicalP-21 is a synthetic cyclic dipeptide — Cyclo(L-prolyl-glycine) — derived from the Selank/Semax C-terminal Pro-Gly-Pro motif.
P-21 Amidate
Nootropic PeptidePreclinicalP-21 Amidate is the amide-modified variant of P-21, the cyclic dipeptide derived from Selank.
Semax P-21
Nootropic PeptidePreclinicalSemax P-21 is a hybrid synthetic peptide combining structural motifs from Semax and P-21 into a single molecule.
View Full Dosage Guide →
Protocols, calculator & safety for NA-Semax
Research Score
3 PubMed studies
Quality Indicators
Data Completeness
75%Research Credibility
Limited research available
Quick Facts
Half-Life
~20-30 minutes (intranasal, estimated from analog data)
Molecular Weight
893.0 g/mol
Trial Phase
Preclinical
Safety Profile
Low RiskCommon Side Effects
- • Mild nasal irritation
- • Brief alertness spike
Stop Use If
- Pregnancy/lactation
- Active mania
- Known peptide allergy
Research Disclaimer
This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use.
Frequently Asked Questions
What is NA-Semax used for in research?
NA-Semax is the N-acetyl-l-aspartyl variant of Semax — the original ACTH(4-7) Pro-Gly-Pro analog developed at the Russian Academy of Sciences in the 1990s. The aspartate addition at the N-terminus is reported to improve metabolic stability against aminopeptidase cleavage, extending the in vivo half-life from minutes (parent Semax) to plausibly tens of minutes after intranasal dosing.
As of 2026, NA-Semax sits in the same research-peptide tier as standard Semax — it is not FDA-approved for any indication and is sold as a research chemical with limited peer-reviewed primary literature on the acetylated variant specifically. Most published Semax pharmacology applies by analogy, with the caveat that the half-life difference may shift optimal dosing frequency.
Reported nonclinical pharmacology mirrors Semax: BDNF upregulation, dopaminergic modulation in mesolimbic circuits, and increased serotonin and dopamine turnover in the cortex and hippocampus. The N-acetyl modification is reported to improve blood-brain-barrier transport, though direct PK comparisons in published literature remain thin.
What forms does NA-Semax come in?
NA-Semax is available in vials, capsules, and sprays forms.
How much does NA-Semax cost?
Pricing varies by vendor and form.
How do I compare NA-Semax vendors?
Compare prices, payment methods, shipping, and COA scores across 0 vendors.
Research Tools
Related Compounds
View AllAdalank
Nootropic PeptidePreclinicalAdalank is a hybrid research peptide combining structural elements of Adamax (the adamantane-modified Semax analog) and Selank (the anxiolytic Pro-Gly-Pro tuftsin analog).
Adamax
Nootropic PeptidePreclinical / Research compoundAdamax is a synthetic nonapeptide (Ac-MEHFPGPAG-NH2) classified as a designer analog of Semax.
NA-Semax Amidate
Nootropic PeptidePreclinicalNA-Semax Amidate is the C-terminally amidated NA-Semax — the carboxylic acid at the peptide's C-terminus is replaced with an amide group (-NH2), which is reported to further extend metabolic half-life by resisting carboxypeptidase cleavage in addition to the aminopeptidase resistance the N-acetyl group already provides. The practical effect is a peptide with dosing-frequency leverage: where standard Semax often requires 3-4 daily doses to maintain effect, NA-Semax Amidate is reported (in vendor monographs and community usage) to maintain subjective effects on a 1-2x daily schedule.
P-21
Nootropic PeptidePreclinicalP-21 is a synthetic cyclic dipeptide — Cyclo(L-prolyl-glycine) — derived from the Selank/Semax C-terminal Pro-Gly-Pro motif.
P-21 Amidate
Nootropic PeptidePreclinicalP-21 Amidate is the amide-modified variant of P-21, the cyclic dipeptide derived from Selank.
Semax P-21
Nootropic PeptidePreclinicalSemax P-21 is a hybrid synthetic peptide combining structural motifs from Semax and P-21 into a single molecule.